Rigel Pharmaceuticals (RIGL) Posts Q2 Loss of 37c/Sh., Tops Views
RIGL Hot Sheet
EPS Growth %: +20.0%Financial Fact:
Contract revenues from collaborations: 750K
Today's EPS Names:
TARO, BRLI, TLB, More
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 EPS of ($0.37), $0.01 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $395 thousand versus the consensus estimate of $420 thousand.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Jiayuan.com (DATE) Reports In-Line Q1 EPS of 5c; Guides Q2 Revs
- Synopsys, Inc. (SNPS) Misses Q2 EPS by 2c; Issues Confident Q3 Outlook; Guides FY12
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
